Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 913-921

  Capri, Stefano ^a   Perlini, Stefano ^b  

^a CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Ace inhibitor; Cardiovascular diseases; Cost effectiveness analysis; Costs; Ramipril

Indexed keywords

RAMIPRIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; ITALY; LABORATORY TEST; MEDICAL FEE; MODEL; OUTPATIENT CARE; PRIMARY PREVENTION; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DELPHI TECHNIQUE; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; RAMIPRIL; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 21244478608     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46331     Document Type: Article

References (27)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
2. World Health Organization. The world health report 1999: Making a difference. Geneva, WHO, 1999
3. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
4. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Tex.: American Heart Association, 2003
5. ISTAT. Tavole di mortalità della popolazione italiana per provincia e regione di residenza. Anno 1998. Istituto Nazionale di Statistica, Rome, 2001
6. Linstone H, Turoff M. The Delphi method: Techniques and applications. Reading, MA: Addison-Wesley, 1975
7. L'Informatore Farmaceutico. Aggiornamento Giugno 2004 (Italian National Formulary). Milan, OEMF, 2004
8. Ministry of Health. Nomenclature tariffario delle prestazioni specialistiche ambulatoriali e successive modificazioni e integrazioni ex dgr n 229 del 03/03/1997 (Outpatient services tariffs). Rome, 2004
9. Ministry of Health. Tariffe delle prestazioni di assistenza ospedaliera per acuti erogate in regime di ricovero ordinario e diurno ex d.m. 30.06.1997 espresse in euro (DRGs tariffs). Rome, 2004
10. Levy E, Gabriel S, Dinet J. The Comparative Medical Costs of Atherothrombotic Disease in European Countries. Pharmacoeconomics 2003;21:651-9
11. Ministry of Health. Rapporto annuale sull'attività di ricovero ospedaliero - Dati SDO 2001 (Hospital casemix). Rome, 2004
12. NICE. Guide to the Methods of Technology Appraisal, April 2004. Available from www.nice.org.uk/pdf/TAP_Methods.pdf [Last accessed 7 June 2004]
13. Briggs AH, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics 1994;3:95-104
14. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999;319:635-8
15. Keeler EB, Cretin S. Discounting of live-saving and other nonmonetary effects. Manage Sci 1983;29:300-6
16. Viscusi WK. Discounting health effects for medical decisions. In: Sloan FA, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995, pp. 123-45
17. Smith D, Gravelle H. The practice of discounting economic evaluation of health care intervention. Int J Technol Assess Health Care 2001;17:236-43
18. Discounting health care: only a matter of timing? Lancet 1992;340:148-9
19. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001;85: 539-43
20. Björholt I, Andersson FL, Kahan T, et al. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med 2002;251:508-17
21. Hart WM, Rubio-Terres C, Margalet Fernandez I, et al. Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain. An Med Interna 2002;19:515-20
22. Schädlich PK, Brecht JG, Rangoonwala B, et al. Cost effectiveness of ramipril in patients at high risk for cardiovascular events. Economic evaluation of the hope (heart outcomes prevention evaluation) study for Germany from the statutory health insurance perspective. Pharmacoeconomics 2004;22:955-73
23. Buxton, MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: An unavoidable fact of life. Health Economics 1997;6:217-227
24. Lamy A, Yusuf S, Pogue J, et al. Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107: 960-5
25. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;6:782-8
26. American Heart Association. Heart disease and stroke statistics - 2004 Update. Dallas, Tex.: American Heart Association, 2003
27. Carroll CA, Coen MM, Rymer MM. Assessment of the Effect of Ramipril Therapy on Direct Health Care Costs for First and Recurrent Strokes in High-Risk Cardiovascular Patients Using Data from the Heart Outcomes Prevention Evaluation (HOPE) Study. Clinical Therapeutics 2003;25:1248-61